Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 -8.42%58 3-Year Share Buyback Ratio is -5.40 as of Mar. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €9.52 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 960 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 70.52% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. InnoCan Pharma's current 3-Year Share Buyback Ratio was -5.40%.
The historical rank and industry rank for InnoCan Pharma's 3-Year Share Buyback Ratio or its related term are showing as below:
FRA:IP40'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -20.2 Med: -12.5 Max: -5.3
Current: -5.4
During the past 8 years, InnoCan Pharma's highest 3-Year Share Buyback Ratio was -5.30%. The lowest was -20.20%. And the median was -12.50%.
FRA:IP40's 3-Year Share Buyback Ratio is ranked worse than 70.52% of 960
companies
in the Consumer Packaged Goods industry
Industry Median: -0.7
vs FRA:IP40: -5.40
InnoCan Pharma (FRA:IP40) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
InnoCan Pharma 3-Year Share Buyback Ratio Related Terms
FRA:IP40 vs PG, CL, KVUE: 3-Year Share Buyback Ratio Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma 3-Year Share Buyback Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's 3-Year Share Buyback Ratio falls into.
InnoCan Pharma 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -5.40 mean?
InnoCan Pharma (FRA:IP40) has a 3-Year Share Buyback Ratio of -5.40 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #677 out of 960 companies in the Consumer Packaged Goods industry, placing it in the top 70.5%.
Is InnoCan Pharma's 3-Year Share Buyback Ratio too high?
InnoCan Pharma's current 3-Year Share Buyback Ratio is -5.40. Based on the distribution chart, InnoCan Pharma ranks #677 out of 960 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's 3-Year Share Buyback Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #677 out of 960 companies for 3-Year Share Buyback Ratio. This places InnoCan Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Consumer Packaged Goods company?
A good 3-Year Share Buyback Ratio depends on the Consumer Packaged Goods industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for InnoCan Pharma and its competitors. InnoCan Pharma's current 3-Year Share Buyback Ratio is -5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.52, compared to a current price of €1.31 — trading 86.3% below its estimated fair value. The current 3-Year Share Buyback Ratio is -5.40. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current 3-Year Share Buyback Ratio is -5.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.31 is trading 86.3% below its estimated GF Value™ of €9.52.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
3-Year Share Buyback Ratio: -5.40
GF Value™: €9.52 vs. price of €1.31 (86.3% below fair value)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score
Get the complete analysis for FRA:IP40
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
